Als 101

Als101 Art Addiction Ap 101 is an investigational human derived antibody directed against misfolded superoxide dismutase 1 (sod1) designed to inhibit the spread of sod1 pathology in the cns of als patients . Als is a neurodegenerative disease marked by loss of motor neurons, the specialized nerve cells that facilitate voluntary movement and muscle control. als symptoms of progressive muscle weakness affect movement, speaking, swallowing, and breathing.

Als Alternative Als 101 A phase 2a, multicenter, randomized, double blind, placebo controlled study to evaluate safety, tolerability, pharmacodynamic markers, and pharmacokinetics of ap 101 in patients with familial amyotrophic lateral sclerosis (fals) and sporadic amyotrophic lateral sclerosis (sals). "we are excited by the topline phase 2 results of ap 101 for als, a devastating degenerative disease for which new treatments are urgently needed," said michael salzmann, phd, chief executive officer, al s pharma. Al s pharma is currently preparing for a confirmatory phase 3 clinical trial of ap 101 in als aimed to initiate end of 2026. Ap 101 is a human antibody directed against misfolded superoxide dismutase 1 (sod1) .the phase 2 trial will assess safety, tolerability, pharmacokinetics and pharmacodynamics of ap 101 both in patients with familial als with disease causing sod1 mutations and in patients with sporadic forms of als.".

Als Alternative Als 101 Al s pharma is currently preparing for a confirmatory phase 3 clinical trial of ap 101 in als aimed to initiate end of 2026. Ap 101 is a human antibody directed against misfolded superoxide dismutase 1 (sod1) .the phase 2 trial will assess safety, tolerability, pharmacokinetics and pharmacodynamics of ap 101 both in patients with familial als with disease causing sod1 mutations and in patients with sporadic forms of als.". Al s pharma today announced positive topline results from the phase 2 clinical study evaluating ap 101, a potential first in class, disease modifying treatment for amyotrophic lateral sclerosis (als). Swiss biotech al s pharma announced positive topline results from its phase ii trial (nct05039099) of ap 101, a monoclonal antibody targeting misfolded sod1 in amyotrophic lateral sclerosis (als). Ap 101 is an investigational human derived antibody therapeutic that selectively targets the misfolded, toxic form of sod1 to disrupt progressive spread of als. data featured in oral presentation at the ad pd™ 2026 international conference on alzheimer’s and parkinson’s diseases. Ap 101 (ni 204) is under development for the treatment of familial amyotrophic lateral sclerosis (fals) and sporadic amyotrophic lateral sclerosis (sals). it is a human recombinant monoclonal antibody.